摘要
目的评价紫杉醇脂质体联合奥沙利铂和替吉奥或5-氟尿嘧啶(5-Fu)双周方案一线治疗晚期胃癌的疗效和安全性。方法收集接受紫杉醇脂质体联合奥沙利铂和替吉奥或5-Fu双周方案治疗的41例有可评估病灶的晚期胃癌患者的临床资料,分析该方案的疗效和安全性。结果 41例患者均可评价疗效,其中完全缓解(CR)3例,部分缓解(PR)23例,疾病稳定(SD)11例,客观有效率(ORR)为63.4%,疾病控制率(DCR)为90.2%。中位无进展生存时间(PFS)为8.5个月,中位总生存时间(OS)为18.8个月。常见不良反应为中性粒细胞减少(78.0%)、白细胞减少(75.6%)、恶心呕吐(56.1%)、贫血(48.8%)和肝功能不全(29.3%)。3~4级血液学毒性包括中性粒细胞减少(58.5%)、白细胞减少(24.4%)和血小板减少(4.9%)。未发生4级非血液学毒性,3级非血液学毒性包括恶心呕吐(4.9%)、腹泻(2.4%)、肝功能不全(2.4%)。无化疗相关性死亡病例。结论紫杉醇脂质体联合奥沙利铂和替吉奥或5-Fu双周方案在晚期胃癌的一线治疗中疗效肯定,且耐受性好。
Objective To evaluate the efficacy and safety of biweekly paclitaxel liposome combined with oxaliplatin and S-1/5-fluorouracil(5-Fu) as first-line treatment in advanced gastric cancer. Method Clinical data of 41 patients with advanced measurable gastric cancer who received biweekly paclitaxel liposome combined with oxaliplatin and S-1/5-Fu regimen was collected and analyzed for efficacy and safety. Result All 41 patients achieved evaluable efficacy, among which 3 achieved complete response(CR), 23 achieved partial response(PR) and 11 achieved stable disease(SD) with objective response rate(ORR) of 63.4% and disease control rate(DCR) of 90.2%. The median progression-free survival time(PFS) and overall survival time(OS) were 8.5 months and 18.8 months, respectively. The most common toxicities were neutropenia(78.0%), leucopenia(75.6%), nausea/vomiting(56.1%), anemia(48.8%) and impaired liver function(29.3%). Grade 3-4 hematological toxicities included neutropenia(58.5%), leucopenia(24.4%) and thrombocytopenia(4.9%). No grade 4 non-hematological toxicity was observed. Grade 3 non-hematological toxicities included nausea/vomiting(4.9%), diarrhea(2.4%) and impaired liver function(2.4%). There was no treatment-related death. Conclusion The regimen of biweekly paclitaxel liposome combined with oxaliplatin and S-1/5-Fu is effective and tolerable as first-line treatment in advanced gastric cancer.
作者
李群
宋岩
王玺
汪麟
莫红楠
张昕
黄镜
LI Qun;SONG Yan;WANG Xi;WANG Lin;MO Hongnan;ZHANG Xin;HUANG Jing(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《癌症进展》
2019年第22期2662-2665,2681,共5页
Oncology Progress
基金
国家重点基础研究发展计划（973计划）（2015CB553902）
关键词
晚期胃癌
紫杉醇脂质体
奥沙利铂
替吉奥
化疗
advanced gastric cancer
paclitaxel liposome
oxaliplatin
S-1
chemotherapy
